Symbols

NBIX

Neurocrine Biosciences·NASDAQ

--(--)

NBIX fundamentals

NBIX Q4 2025 Earnings

Neurocrine Biosciences (NBIX) released its earnings on Feb 11, 2026: revenue was 805.50M (YoY +28.33%), beat estimates; EPS was 1.48 (YoY +48.00%), missed estimates.

Revenue / YoY

805.50M

+28.33%

EPS / YoY

1.48

+48.00%

Report date

Feb 11, 2026

NBIX Earnings Call Summary for Q4,2025

Revenue Growth: 2025 total sales $2.8B (+22% YoY), INGREZZA $2.5B (+9% YoY), CRENESSITY $300M. 2026 INGREZZA guidance $2.7B-$2.8B (+10%).
Pipeline Momentum: Phase III data for osavampator (MDD) and direclidine (schizophrenia) expected in 2027. NBI-890 VMAT2 inhibitor Phase II initiated.
CRENESSITY Expansion: 2026 sales force expansion and AI-driven targeting to reach 10%+ patient penetration. Pediatric study for <4 years old patients underway.
Financial Strength: $2.5B cash, 30% non-GAAP margin, and $850M operating income in 2025. 2026 R&D expenses to grow with pipeline advancement.

Earnings

EPS

Revenue

Revenue & Expenses

NBIX has released its 2025 Q4 earnings report, with revenue of 805.50M, reflecting a YoY change of 28.33%, and net profit of 153.70M, showing a YoY change of 49.08%. The Sankey diagram below clearly presents NBIX's revenue sources and cost distribution.

Key Indicators

Neurocrine Biosciences (NBIX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Neurocrine Biosciences (NBIX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Neurocrine Biosciences (NBIX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Neurocrine Biosciences (NBIX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown